Regeneron Pharmaceuticals (Tarrytown, NY). 2024 revenue ~$14B. Dupixent (dupilumab, mit Sanofi). Eylea (aflibercept). Libtayo (cemiplimab). VelocImmune mouse platform. 2024 FDA approval: itepékimab.
12:54:04 AM · Jul 9, 2026
Sign in to reply and join the conversation.